ncRNA basic information ncRNA ID: MI0000483 ncRNA Database: miRBase ncRNA Name: miR-186 ncRNA Type: miRNA ncRNA Expression: up-regulated ncRNA Method: RT-PCR ncRNA Target Gene: YY1 ncRNA Pathway: NA Evidence (ncRNA-drug): validated

drug basic information Drug ID: DB00515 (APRD00359) Drug Name: Cisplatin Drug Method: In this study, using western blot analysis, we found that Yin Yang 1 (YY1) expression was increased in cisplatin-resistant glioblastoma U87MG cells (U87MG-CR). We observed that the silencing of YY1 sensitized the U87MG-CR cells to cisplatin and that the overexpression of YY1 promoted the resistance of LN-229 glioblastoma cells to cisplatin, as shown by MTT assay. Using sphere formation assay, we also found that the silencing of YY1 inhibited the formation of the glioblastoma-initiating cell (GIC) phenotype in the U87MG-CR cells. In addition, the results of RT-qPCR revealed that miR-186 expression was decreased in U87MG-CR cells. Using RT-PCR and western blot analysis, we observed that overexpression of miR-186 inhibited YY1 expression in U87MG-CR cells. The overexpression of miR-186 also reversed cisplatin resistance and the formation of the GIC phenotype in glioblastoma cells. On the whole, the findings of this study demonstrate that miR-186 reverses cisplatin resistance and inhibits the formation of the GIC phenotype by degrading YY1 in glioblastoma. Drug Response: sensitive

Cancer basic information Cancer: glioblastoma Tissue/Cell: cell line (U87MG,U87MG-CR)

Other information Title: miR-186 reverses cisplatin resistance and inhibits the formation of the glioblastoma-initiating cell phenotype by degrading Yin Yang 1 in glioblastoma. Journal: Int J Mol Med Published: 2019 PubMed ID: 30365062